Halozyme
HALO
316 hedge funds and large institutions have $5.02B invested in Halozyme in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 113 increasing their positions, 124 reducing their positions, and 37 closing their positions.
532% more call options, than puts
Call options by funds: $21.6M | Put options by funds: $3.41M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
1.27% more ownership
Funds ownership: 91.91% → 93.19% (+1.3%)
3% less capital invested
Capital invested by funds: $5.19B → $5.02B (-$174M)
9% less repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 124
2% less funds holding
Funds holding: 324 → 316 (-8)
11% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$21.9M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$17M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$13.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.9M |
| 5 |
SAM
Silvercrest Asset Management
New York
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$28.6M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$21.3M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$15.8M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$11.2M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$9.99M |
HALO Hedge Fund Activity: Q1 2022 in Review
316 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q1 2022, worth a combined $5.02B — down 3.4% from $5.19B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of HALO and 33 opened new positions — a net loss of 4 holders — while 124 trimmed existing stakes and 113 added.
The largest buyer was Lombard Odier Asset Management (Switzerland), opening a new position worth an estimated $21.9M. The largest seller was Goldman Sachs, cutting an estimated $28.6M.
- 316 institutional investors held Halozyme (HALO) as of Q1 2022, down from 324 in Q4 2021.
- Funds reported $5.02B of Halozyme stock for Q1 2022, down 3.4% quarter-over-quarter.
- 33 funds opened new Halozyme positions in Q1 2022 and 37 closed out, a net change of -4 holders.
- The largest Halozyme buyer in Q1 2022 was Lombard Odier Asset Management (Switzerland), an estimated $21.9M added.
- The largest Halozyme seller in Q1 2022 was Goldman Sachs, an estimated $28.6M sold.
Based on aggregated 13F filings for Q1 2022.